| Name | Title | Contact Details |
|---|
Argonne Capital Group is a Atlanta, GA-based company in the Financial Services sector.
SR Realty Trust, Inc. is a private real estate investment trust, or REIT, formed on September 15, 2014 for the purpose of investing in a diversified portfolio of commercial real estate properties and other real estate related assets. Our portfolio consists of various types of commercial real estate property, including industrial, retail, multi-family residential and single-tenant net leased properties. As of December 31, 2017, SR Realty Trust owns over $110 million in assets. Our primary investment objectives are: • To preserve and protect stockholders` capital • To pay consistent distributions to shareholders, and • To deliver long-term capital appreciation The Company`s investment strategy is to acquire and maintain a diversified portfolio of income-producing commercial real estate assets. Our acquisitions focus on stability and consistency of income, disciplined and controlled growth, and transparency to investors. The Company maintains a long-term, buy-and-hold mentality and may also attempt to capitalize on short-term market considerations to maximize our investments.
Virtus Partners, LLC provides fixed-income Collateral Administrative services and data on structured and non-structured transactions across a broad spectrum of investment vehicles, including Hedge and Private Equity funds, separate accounts, Collateralized Loan Obligations (CLOs), and Total Returns Swaps (TRS). Virtus also provides solutions for fixed-income asset managers looking to outsource their Middle Office requirements. For administrative services requiring a Trustee function, such as CLOs, Virtus has partnered with Citi Agency & Trust to offer a seamless and holistic administrative package.
Nollenberger Capital Partners, Inc. is a San Francisco, CA-based company in the Financial Services sector.
Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.